UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Link zum Volltext

Verfügbarkeit prüfen

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.143-143, Article 143

2019

Link zum Volltext

Verfügbarkeit prüfen

Molecular pathways: autophagy in cancer--a matter of timing and context

Clinical cancer research, 2015-02, Vol.21 (3), p.498-504

2015

Link zum Volltext

Verfügbarkeit prüfen

Autophagy in malignant transformation and cancer progression

The EMBO journal, 2015-04, Vol.34 (7), p.856-880

2015

Link zum Volltext

Verfügbarkeit prüfen

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Genes & development, 2007-07, Vol.21 (13), p.1621-1635

2007

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Link zum Volltext

Verfügbarkeit prüfen

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Link zum Volltext

Verfügbarkeit prüfen

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

Molecular & cellular oncology, 2015-07, Vol.2 (3), p.e975035-e975035

2015

Link zum Volltext

Verfügbarkeit prüfen

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (11), p.4105-4115

2008

Link zum Volltext

Verfügbarkeit prüfen

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567

2022

Link zum Volltext

Verfügbarkeit prüfen

Role and regulation of autophagy in cancer

Biochimica et biophysica acta, 2009-09, Vol.1793 (9), p.1516-1523

2009

Link zum Volltext

Verfügbarkeit prüfen

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity

Autophagy, 2014-11, Vol.10 (11), p.2036-2052

2014

Link zum Volltext

Verfügbarkeit prüfen

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Molecular cancer research, 2009-09, Vol.7 (9), p.1487-1496

2009

Link zum Volltext

Verfügbarkeit prüfen

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5427-5434

2020

Link zum Volltext

Verfügbarkeit prüfen

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Link zum Volltext

Verfügbarkeit prüfen

Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer

Cancer discovery, 2013-08, Vol.3 (8), p.894-907

2013

Link zum Volltext

Verfügbarkeit prüfen

Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges

Journal of translational medicine, 2014-03, Vol.12 (1), p.79-79, Article 79

2014

Link zum Volltext

Verfügbarkeit prüfen

ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss

Autophagy, 2014-04, Vol.10 (4), p.662-676

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Link zum Volltext

Verfügbarkeit prüfen

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Annals of oncology, 2022-07, Vol.33, p.S465

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaCancer

KollektionEZB Free E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(50)
Berichte
(1)

Sprache

Englisch
(51)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(16)
Animals
(14)
Oncology
(13)
Female
(11)
Mice
(11)
Autophagy
(9)
Cell Biology
(9)
Breast Cancer
(8)
Apoptosis
(7)
Beclin-1
(5)
Cancer Therapies
(5)
Chemotherapy
(5)
Monoclonal Antibodies
(5)
Targeted Cancer Therapy
(5)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Cancer Research
(4)
General & Internal Medicine
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pembrolizumab for Early Triple-Negative Breast Cancer

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Molecular pathways: autophagy in cancer--a matter of timing and context

Autophagy in malignant transformation and cancer progression

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Role and regulation of autophagy in cancer

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer

Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges

ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Aktive Filter

Suchergebnisse filtern